Diagnosis and management of pergolide-induced fibrosis

Movement Disorders

Volumn 19, Issue 6, 2004, Pages 699-704

  Agarwal, Pinky ^a   Fahn, Stanley ^a   Frucht, Steven J ^a,b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Pergolide; Pleural fibrosis; Retroperitoneal fibrosis; Surgery

Indexed keywords

LEVODOPA; OXYCODONE; PERGOLIDE; PRAMIPEXOLE; PREDNISONE; STEROID; TAMOXIFEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; MALE; MEDICAL ASSESSMENT; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PLEURA EFFUSION; PLEURAL FIBROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RETROGRADE PYELOGRAPHY; RETROPERITONEAL FIBROSIS; SURGICAL TECHNIQUE; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BIOPSY, NEEDLE; BRONCHI; FEMALE; FIBROSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; PLEURAL DISEASES; RETROPERITONEAL FIBROSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4444334678     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20200     Document Type: Article

References (17)

1. Shaunak S, Wilkins A, Pilling JB, et al. Pericardial, pleural and retroperitoneal fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999;66:79-81.
2. Balachandran KP, Stewart D, Berg GA, Oldroyd KG. Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide. Postgrad Med J 2002;78:49-50.
3. Danoff SK, Grasso ME, Terry PB, Flynn JA. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001;120:313-316.
4. Kunkler RB, Osborn DE, Abbott RJ. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease. Br J Urol 1998;82:147.
5. Mondal BK, Suri S. Pergolide induced retroperitoneal fibrosis. Int J Clin Pract 2000;54:403.
6. Jiménez-Jiménez FJ, López-Alvarez J, Sánchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995;18:277-279.
7. Pritchett AM, Morrsion JF, William ED, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking Pergolide. Mayo Clinic Proc 2002;77:1280-1286.
8. Lund BC, Neiman RF, Perry PJ. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy 1999;19:1437-1438.
9. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30:613-616.
10. Flowers CM, Racoosin JA, Lu SL, Beitz JL. The US food and drug administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-731.
11. Kastelik JA, Aziz I, Greenstone MA, Thomopson R, Morice AH. Pergolide-induced lung disease in patients with Parkinson's disease. Respir Med 2002;96:548-550.
12. Camp GV, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859-861.
13. Bleumink GS, van der Molen-Eijgenraam M, Strijbos JH, Sanwikarja S, van Puijenbroek EP, Stricker BHC. Pergolide-induced pleuropulmonary fibrosis. Clin Neuropharmacol 2002;25:290-293.
14. Varsano S, Gershman M, Hamaoui E. Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema. Respiration 2000; 67:580-582.
15. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (in press).
16. Morelock SY, Sahn SA. Drugs and the pleura. Chest 1999;116: 212-221.
17. Duffy SM, Lawley WJ, Kaur D, Yang W, Bradding P. Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation. J Allergy Clin Immunol 2003;112:965-972.